TY - JOUR
T1 - Amyloidosis
AU - Gertz, Morie A.
AU - Lacy, Martha Q.
AU - Dispenzieri, Angela
AU - Hayman, Suzanne R.
N1 - Funding Information:
Supported in part by the Hematologic Malignancies Fund from Mayo Clinic.
PY - 2005/12
Y1 - 2005/12
N2 - Amyloidosis is an uncommon plasma-cell dyscrasia with an incidence of eight patients per million per year. It is often difficult to recognize because of the myriad symptoms and vague nature of the clinical presentation. Symptoms include fatigue, dyspnea, edema, paresthesias, and weight loss. Clinical syndromes at presentation include nephrotic-range proteinuria with or without renal insufficiency, cardiomyopathy, hepatomegaly, symptomatic peripheral neuropathy, and autonomic failure. Recent advances have occurred in evaluation of patients by using the free light chain assay and new prognostic assessments with cardiac biomarkers. Newly developed therapeutic strategies, involving high-dose and intermediate-dose chemotherapy, have evolved in the last 3 years. This paper reviews a diagnostic pathway clinicians can use to diagnose the disorder, assess a patient's prognosis, and logically plan a therapeutic strategy.
AB - Amyloidosis is an uncommon plasma-cell dyscrasia with an incidence of eight patients per million per year. It is often difficult to recognize because of the myriad symptoms and vague nature of the clinical presentation. Symptoms include fatigue, dyspnea, edema, paresthesias, and weight loss. Clinical syndromes at presentation include nephrotic-range proteinuria with or without renal insufficiency, cardiomyopathy, hepatomegaly, symptomatic peripheral neuropathy, and autonomic failure. Recent advances have occurred in evaluation of patients by using the free light chain assay and new prognostic assessments with cardiac biomarkers. Newly developed therapeutic strategies, involving high-dose and intermediate-dose chemotherapy, have evolved in the last 3 years. This paper reviews a diagnostic pathway clinicians can use to diagnose the disorder, assess a patient's prognosis, and logically plan a therapeutic strategy.
KW - Amyloid
KW - Amyloidosis
KW - Cardiomyopathy
KW - Monoclonal gammopathy
KW - Multiple myeloma
KW - Nephrotic syndrome
KW - Stem-cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=22144472237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22144472237&partnerID=8YFLogxK
U2 - 10.1016/j.beha.2005.01.030
DO - 10.1016/j.beha.2005.01.030
M3 - Review article
C2 - 16026746
AN - SCOPUS:22144472237
SN - 1521-6926
VL - 18
SP - 709
EP - 727
JO - Best Practice and Research: Clinical Haematology
JF - Best Practice and Research: Clinical Haematology
IS - 4 SPEC. ISS.
ER -